ÂÜÀòÂÒÂ×

Alexander Polinsky is the current CEO and founder of OncoTartis, a position they have held since December of 2018. Prior to their current role, they served as the CEO of Everon Biosciences from January 2010 to December 2018. Alexander was also a venture partner at Maxwell Biotech Venture Fund from December 2009 to May 2013. Before that, they worked as the Vice President of Global Technology at Pfizer R&D from May 1999 to April 2007, where they were responsible for bringing advanced technologies into the company and managing their implementation and dissemination. Prior to their work at Pfizer, they were the Cofounder and CSO at Alanex Corporation from April 1991 to May 1999, where they created the research organization, invented and managed new high speed synthesis and computational drug design technologies, and was responsible for all scientific programs and external collaborations. After Alanex was acquired by Agouron Pharmaceuticals in 1997, then by Warner Lamber in 1999, and then by Pfizer in 2000, they managed the integration of the research organization and technologies into the larger pharma organization.

Alexander Polinsky has a Ph.D. in Chemistry from Moscow University and an MS in Chemistry from the same school.

Some individuals on their team include Aleksandra Kotlyarova - Director of Operations, Olga Chernova - Founder & VP, Research, and Eric Rowinsky - Chief Medical Officer.